Labaton Keller Sucharow and their co-lead counsel secured a $10,000,000 settlement in a securities class action lawsuit.
The operative consolidated amended complaint in the action (the “Complaint”) asserted claims against: (a) Athira and the Individual Defendants under Section 10(b) and Section 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder; (b) all Defendants under Sections 11 and 12(a)(2) of the Securities Act with respect to the Company’s Initial Public Offering and Secondary Public Offering; and (c) the Individual Defendants under Section 15 of the Securities Act with respect to the Company’s IPO and SPO. Among other things, the Complaint alleged that Defendants made materially false and misleading statements and/or failed to disclose that the Company’s president and chief executive officer, Dr. Kawas, had improperly enhanced images in certain research papers she co-authored that were published from 2011 to 2014, which were referenced in certain applications by Washington State University (“WSU”) for patents that were then exclusively licensed to Athira. The Complaint further alleged that, when information regarding the allegedly enhanced images was publicly disclosed, the Company’s stock price was negatively impacted. The Complaint is available for review on the Settlement Website.
The case is Nacif et al., v. Athira Pharma, Inc. et al., Case No.: 2:21-cv-00861-TSZ, in the United States District Court for the Western District of Washigton. The Action is assigned to the Honorable Thomas S. Zilly, United States District Judge. Labaton Keller Sucharow represents Antonio Bachaalani Nacif and Wies Rafi.
Submit Claim Form
If you purchased or otherwise acquired Athira Pharma, Inc. (“Athira” or the “Company”) publicly traded common stock during the period from September 17, 2020, through June 17, 2021, inclusive (the “Class Period”), and were damaged thereby, you may be entitled to a payment from a class action settlement. To be eligible for a payment, you must submit a Claim Form to the Claims Administrator by September 6, 2024.
Settlement Hearing
The Final Approval Hearing was held on October 25, 2024.
If you have questions about the Settlement, please contact Labaton Keller Sucharow at settlementquestions@labaton.com or (888) 219-6877, or contact the Claims Administrator, at 866-274-4004.
Additional information about the Settlement can also be found at www.AthiraSecuritiesSettlement.com.
